What are the ASCO guidelines for chemotherapy for stage IV non–small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

The American Society of Clinical Oncology (ASCO) issued guidelines on chemotherapy for stage IV NSCLC in 2015 [215] and updated them in 2017. [222] For patients with performance status (PS) 0 to 1 who receive chemotherapy (and for selected well-informed patients with PS 2 who desire aggressive treatment), ASCO recommends therapy with a combination of two cytotoxic drugs. Platinum combinations, unless contraindicated, are recommended over nonplatinum therapy. In addition, ASCO recommends early palliative care assistance for all patients with stage IV NSCLC, because it improves survival and well-being in patients with this incurable condition. [215]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!